Companies › CSPC ZhongQi Pharmaceutical Technology
16 active drug programs in 118 registered trials: 58 Phase 2, 44 Phase 1, 13 Phase 3, 3 Phase 4; Oncology, Gastroenterology, Other, Respiratory; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DP303c Antibody-drug conjugate (ADC) | – | Phase 3 | HER2-positive Breast Cancer; Advanced Solid Tumors | Oct 2027 |
| Mitoxantrone DNA topoisomerase II alpha inhibitor | TOP2A | Phase 3 | Peripheral T Cell Lymphoma; Acute Myeloid Leukaemia; B-cell Acute Lymphoblastic Leukemia; Soft Tissue Sarcoma … | Dec 2027 |
| Glumetinib MEK inhibitor | MAP2K1 | Phase 2 | Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors | Apr 2027 |
| CM326 Unclear - not stated in registry | – | Phase 2 | Chronic Obstructive Pulmonary Disease | Jul 2027 |
| SYHX2008 injection Somatostatin somatostatin receptor 2 (SSTR2) agonist | – | Phase 2 | Gastrointestinal Neuroendocrine Pancreatic Tumor | Aug 2027 |
| Sirolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 2 | HR+/HER2- Advanced/Metastatic Breast Cancer; Gastroenteropancreatic Neuroendocrine Tumors; Advanced Solid Tumors; Antiphospholipid (aPL)-Positive … | Oct 2027 |
| Octreotide Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors; Pancreas Head Cancer | Aug 2028 |
| CM310 Recombinant humanized monoclonal antibody | – | Phase 2 | Moderate to Severe Asthma | May 2032 |
| Ammoxetine hydrochloride Enteric-coated Tablets (new formulation) norepinephrine-dopamine reuptake inhibitor | SLC6A3 | Phase 1 | Healthy Participants | Nov 2026 |
| SYH2085 | – | Phase 1 | Healthy Participants | Nov 2026 |
| SKLB1028 | – | Phase 1 | Newly Diagnosed Acute Myeloid Leukemia (AML) | Dec 2026 |
| SYH2082 Injection | – | Phase 1 | Overweight or Obesity | Jan 2027 |
| SYS6002 Antibody-drug conjugate (ADC) | – | Phase 1 | Advanced Solid Tumors | Oct 2027 |
| SYS6010 Antibody-drug conjugate (ADC) | – | Phase 1 | Advanced Solid Tumors | Oct 2027 |
| SYS6043 Antibody-drug conjugate (ADC) | – | Phase 1 | Advanced Solid Tumors | Oct 2027 |
| SYS6020 injection Autologous CAR-T cells transfected with LNP-mRNA targeting BCMA | – | Phase 1 | Myasthenia Gravis | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05299164 | Mitoxantrone | Phase 1 | Non Hodgkin Lymphoma | Oncology | Dec 2023 |
| NCT05299164 | Mitoxantrone | Phase 1 | Non Hodgkin Lymphoma | Oncology | Dec 2023 |
| NCT05299164 | Mitoxantrone | Phase 1 | Non Hodgkin Lymphoma | Oncology | Dec 2023 |
| NCT05299164 | Mitoxantrone | Phase 1 | Non Hodgkin Lymphoma | Oncology | Dec 2023 |
| NCT06220097 | Mitoxantrone | Phase 2 | B-cell Acute Lymphoblastic Leukemia | Oncology | Aug 2024 |
| NCT04582136 | Sirolimus | Phase 3 | Systemic Lupus Erythematosus | Immunology | Apr 2025 |
| NCT05464433 | Mitoxantrone | Phase 1 | Extranodal Natural Killer T Cell Lymphoma | Oncology | Apr 2025 |
| NCT06957379 | Sirolimus | Phase 2 | HR+/HER2- Advanced/Metastatic Breast Cancer | Oncology | Jun 2025 |
| NCT03150914 | Sirolimus | Phase 3 | LAM | Infectious disease | Jun 2025 |
| NCT05836025 | Sirolimus | Phase 2 | Perimenopausal | Genitourinary | Oct 2025 |
| NCT02574728 | Sirolimus | Phase 2 | Cancer | Oncology | Jun 2026 |
| NCT01087554 | Sirolimus | Phase 1 | Advanced Cancer | Oncology | Aug 2026 |
| NCT07756996 | Ammoxetine hydrochloride Enteric-coated Tablets (new formulation) | Phase 1 | Healthy Participants | Other | Aug 2026 |
| NCT04742777 | Sirolimus | Phase 2 | Aging | Other | Oct 2026 |
| NCT07694869 | Ammoxetine hydrochloride Enteric-coated Tablets (new formulation) | Phase 1 | Healthy Participants | Genitourinary | Nov 2026 |
| NCT07412353 | SYH2085 | Phase 1 | Healthy Participants | Other | Nov 2026 |
| NCT07694843 | Ammoxetine hydrochloride Enteric-coated Tablets (new formulation) | Phase 1 | Healthy Participants | Gastroenterology | Nov 2026 |
| NCT06246162 | Mitoxantrone | Phase 1 | Multiple Myeloma | Oncology | Nov 2026 |
| NCT05384756 | Sirolimus | Phase 1 | Sickle Cell Disease | Hematology | Dec 2026 |
| NCT06514313 | Mitoxantrone | Phase 2 | Soft Tissue Sarcoma | Oncology | Dec 2026 |
| NCT04948203 | Sirolimus | Phase 2 | Pulmonary Fibrosis | Respiratory | Dec 2026 |
| NCT03099356 | Sirolimus | Phase 2 | Metastatic Thyroid Cancer | Oncology | Dec 2026 |
| NCT03258320 | Mitoxantrone | Phase 2 | Prostate Cancer Patients | Oncology | Dec 2026 |
| NCT06429449 | Mitoxantrone | Phase 1 | Leukemia | Oncology | Dec 2026 |
| NCT06673290 | Sirolimus | Phase 2 | Lymphatic Malformation | Other | Dec 2026 |
| NCT05958719 | Mitoxantrone | Phase 2 | Peripheral T Cell Lymphoma | Oncology | Dec 2026 |
| NCT03901001 | Sirolimus | Phase 3 | Influenza | Infectious disease | Dec 2026 |
| NCT06960928 | Sirolimus | Phase 3 | Long COVID-19 | Infectious disease | Dec 2026 |
| NCT06091332 | Sirolimus | Phase 2 | Cavernous Malformations | Neurology | Dec 2026 |
| NCT05426252 | Sirolimus | Phase 1 | Thalassemia in Children | Hematology | Dec 2026 |
| NCT06345365 | Mitoxantrone | Phase 3 | Acute Myeloid Leukaemia | Oncology | Dec 2026 |
| NCT06621212 | Mitoxantrone | Phase 2 | Relapsed/Refractory Acute Myeloid Leukaemia | Oncology | Dec 2026 |
| NCT06651866 | Mitoxantrone | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT05445154 | SKLB1028 | Phase 1 | Newly Diagnosed Acute Myeloid Leukemia (AML) | Oncology | Dec 2026 |
| NCT04375813 | Sirolimus | Phase 2 | Non-muscle Invasive Bladder Cancer | Oncology | Jan 2027 |
| NCT06802055 | Sirolimus | Phase 2 | Aplastic Anaemia | Hematology | Jan 2027 |
| NCT07532655 | SYH2082 Injection | Phase 1 | Overweight or Obesity | Metabolic and endocrine | Jan 2027 |
| NCT03243019 | Sirolimus | Phase 2 | Lymphatic Malformation | Other | Feb 2027 |
| NCT04375631 | Mitoxantrone | Phase 1 | Recurrent Acute Myeloid Leukemia | Oncology | Feb 2027 |
| NCT04629495 | Sirolimus | Phase 2 | Mild Cognitive Impairment | Neurology | Mar 2027 |
| NCT05949658 | Sirolimus | Phase 1 | Aging | Other | Mar 2027 |
| NCT04959175 | Sirolimus | Phase 1 | Hematologic Neoplasms | Oncology | Apr 2027 |
| NCT06947291 | Glumetinib | Phase 2 | Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors | Oncology | Apr 2027 |
| NCT03192397 | Sirolimus | Phase 1 | Acute Myeloid Leukemia in Remission | Oncology | May 2027 |
| NCT05036226 | Sirolimus | Phase 1 | Prostate Cancer Recurrent | Oncology | May 2027 |
| NCT06447090 | Mitoxantrone | Phase 2 | Relapse Acute Myeloid Leukemia | Oncology | May 2027 |
| NCT06447090 | Mitoxantrone | Phase 2 | Relapse Acute Myeloid Leukemia | Oncology | May 2027 |
| NCT07058974 | Sirolimus | Phase 1 | Smokers | Other | Jun 2027 |
| NCT05436418 | Sirolimus | Phase 1 | Peripheral Blood Stem Cell Transplantation | Oncology | Jun 2027 |
| NCT05104983 | Sirolimus | Phase 2 | Tuberous Sclerosis Complex | Neurology | Jun 2027 |
| NCT07418736 | CM326 | Phase 2 | Chronic Obstructive Pulmonary Disease | Respiratory | Jul 2027 |
| NCT06594640 | Mitoxantrone | Phase 1 | Diffuse Large B-cell Lymphoma | Oncology | Jul 2027 |
| NCT06505395 | SYHX2008 injection | Phase 2 | Gastrointestinal Neuroendocrine Pancreatic Tumor | Gastroenterology | Aug 2027 |
| NCT07093710 | Mitoxantrone | Phase 1 | Peripheral T Cell Lymphoma | Oncology | Aug 2027 |
| NCT06494150 | Sirolimus | Phase 2 | Low Grade Ovarian Serous Adenocarcinoma | Oncology | Aug 2027 |
| NCT06486337 | Mitoxantrone | Phase 2 | NHL | Oncology | Aug 2027 |
| NCT07131644 | Sirolimus | Phase 2 | Kaposiform Hemangioendothelioma | Oncology | Sep 2027 |
| NCT06727305 | Sirolimus | Phase 1 | Aging | Other | Sep 2027 |
| NCT07262957 | Octreotide | Phase 4 | Pancreas Head Cancer | Oncology | Sep 2027 |
| NCT02042326 | Sirolimus | Phase 2 | Arteriovenous Malformations | Other | Sep 2027 |
The 60 nearest readouts of 118 trials; the rest in the app.
Novartis Sinotau Pharmaceutical Group HTA RayzeBio Axsome Therapeutics Roche ITM Solucin Advanced Accelerator Applications RECORDATI GROUP Debiopharm International
Merck KGaA Ono Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai Henlius Biotech Mabwell (Shanghai) Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.